Carlos Kiffer
Overview
Explore the profile of Carlos Kiffer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
77
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gill C, Aktab E, Alfouzan W, Bourassa L, Brink A, Burnham C, et al.
Open Forum Infect Dis
. 2022 Feb;
9(2):ofab617.
PMID: 35106312
Background: Carbapenemase-producing, carbapenem-resistant (CP-CRPA) is a global challenge. However, detection efforts can be laborious because numerous mechanisms produce carbapenem resistance. A minimum inhibitory concentration-based algorithm (imipenem- or meropenem-resistant plus ceftazidime-nonsusceptible...
2.
Gill C, Aktas E, Alfouzan W, Bourassa L, Brink A, Burnham C, et al.
Antimicrob Agents Chemother
. 2021 Aug;
65(11):e0120421.
PMID: 34398670
The present study evaluated the potency of ceftazidime and cefepime among carbapenem-resistant Pseudomonas aeruginosa isolates collected as part of a global surveillance program and assessed the pharmacodynamic implications using previously...
3.
Gill C, Aktab E, Alfouzan W, Bourassa L, Brink A, Burnham C, et al.
Eur J Clin Microbiol Infect Dis
. 2021 Jul;
40(12):2533-2541.
PMID: 34291323
The cephalosporin-β-lactamase-inhibitor-combinations, ceftolozane/tazobactam and ceftazidime/avibactam, have revolutionized treatment of carbapenem-resistant Pseudomonas aeruginosa (CR-PA). A contemporary assessment of their in vitro potency against a global CR-PA collection and an assessment of...
4.
Abboud C, Rao G, Souza E, Zavascki A, Kiffer C
Braz J Infect Dis
. 2017 Nov;
22(1):51-54.
PMID: 29182906
A retrospective cohort study, were evaluated: polymyxin B plus aminoglycosides or polymyxin B plus other antibiotics. Any degree of acute kidney injury occurred in 26 (86.6%) patients. The median time...
5.
Padoveze M, Fortaleza C, Kiffer C, Barth A, Carneiro I, Giamberardino H, et al.
Am J Infect Control
. 2015 Sep;
44(1):74-9.
PMID: 26412480
Background: Minimal structure is required for effective prevention of health care-associated infection (HAI). The objective of this study was to evaluate the structure for prevention of HAI in a sample...
6.
Mouro A, Kiffer C, Koga P, Monteiro A, Camargo E, Pignatari A
Braz J Infect Dis
. 2012 Jan;
15(5):462-6.
PMID: 22230853
Objectives: To examine the spatial distribution of Streptococcus pneumoniae and its clonal patterns collected between 2002 and 2006 in São Paulo, Brazil. Methods: As part of an observational study in...
7.
Kiffer C, Hsiung A, Oplustil C, Sampaio J, Sakagami E, Turner P, et al.
Braz J Infect Dis
. 2005 Oct;
9(3):216-24.
PMID: 16224628
Establish the susceptibility pattern of Gram-negative bacteria causing infections in ICU patients, MYSTIC Program Brazil 2003. Gram-negative bacteria (n = 1,550) causing nosocomial infections were collected at 20 Brazilian centers....
8.
Mendes C, Oplustil C, Sakagami E, Turner P, Kiffer C
Braz J Infect Dis
. 2005 Jun;
9(1):44-51.
PMID: 15947846
Objective: Establish the susceptibility pattern of Gram-negative bacteria causing infections in ICU patients, MYSTIC Program Brazil 2002. Material And Methods: Gram-negative bacteria (n = 503) causing nosocomial infections were collected...
9.
Mendes C, Kiffer C, Segura A, Ribeiro J, Turner P
Braz J Infect Dis
. 2004 Aug;
8(1):109-11.
PMID: 15286882
A Klebsiella pneumoniae strain was isolated from the urine of a patient at one of the centers participating in the 2001 edition of the MYSTIC program in Brazil. The initial...